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Objectives: To investigate the relationship between MIC and clinical outcome in a randomized controlled trial
that compared gentamicin 240 mg plus azithromycin 1 g with ceftriaxone 500 mg plus azithromycin 1 g. MIC
analysis was performed on Neisseria gonorrhoeae isolates from all participants who were culture positive before
they received treatment.
Methods: Viable gonococcal cultures were available from 279 participants, of whom 145 received ceftriaxone/
azithromycin and 134 received gentamicin/azithromycin. Four participants (6 isolates) and 14 participants (17
isolates) did not clear infection in the ceftriaxone/azithromycin and gentamicin/azithromycin arms, respectively.
MICs were determined by Etest on GC agar base with 1% Vitox. The geometric mean MICs of azithromycin, cef-
triaxone and gentamicin were compared using logistic and linear regression according to treatment received
and N. gonorrhoeae clearance.
Results: As the azithromycin MIC increased, gentamicin/azithromycin treatment was less effective than cef-
triaxone/azithromycin at clearing N. gonorrhoeae. There was a higher geometric mean MIC of azithromycin for
isolates from participants who had received gentamicin/azithromycin and did not clear infection compared with
those who did clear infection [ratio 1.95 (95% CI 1.28–2.97)], but the use of categorical MIC breakpoints did not
accurately predict the treatment response. The geometric mean MIC of azithromycin was higher in isolates from
the pharynx compared with genital isolates.
Conclusions: We found that categorical resistance to azithromycin or ceftriaxone in vitro, and higher gentamicin
MICs in the absence of breakpoints, were poorly predictive of treatment failure.
Introduction
Controlling gonorrhoea is challenging owing to the high number of
cases,1–3 patient compliance in avoiding unprotected sex while
being treated4,5 and the ability of Neisseria gonorrhoeae to con-
tinually develop antimicrobial resistance.6 To preserve the last
remaining clinically demonstrated monotherapy option, ceftriax-
one, a dual-therapy regimen of ceftriaxone and azithromycin has
been established. Intramuscular ceftriaxone 500 mg plus oral
azithromycin 1 g was recommended in the UK until January
2019,7 with similar dual-therapy regimens currently recom-
mended in other countries.8 Dual therapy was introduced primarily
owing to increasing resistance to orally administered cefixime,
especially in MSM. One of the main reasons to include azithromycin
was to provide cover in the event of ceftriaxone failing, thereby
delaying the emergence of resistance to ceftriaxone. Other rea-
sons stated in the 2011 UK gonorrhoea management guidelines7
included cover for chlamydia treatment, limited evidence of syn-
ergy between ceftriaxone and azithromycin and improved clear-
ance of pharyngeal gonorrhoea when azithromycin is combined
with a cephalosporin. Increasing azithromycin resistance and
decreasing ceftriaxone susceptibility is being observed globally,9,10
along with documented sustained transmission of isolates with
very high-level azithromycin resistance (MIC 256 mg/L).11 These
concerning antimicrobial susceptibility profiles, along with verified
VC Crown copyright 2019.
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treatment failures using both ceftriaxone and azithromycin,12,13
are clear evidence that trials to establish the effectiveness of alter-
native antibiotic regimens are needed.9
A recent randomized controlled trial in the UK, ‘Gentamicin in
the Treatment of Gonorrhoea (G-ToG)’, compared gentamicin
240 mg plus azithromycin 1 g with the current first-line treatment
of gonorrhoea.5 The primary endpoint was clearance of
N. gonorrhoeae using a nucleic acid amplification test (NAAT)
2 weeks post-treatment. The study revealed that gentamicin, in
combination with azithromycin, had a lower cure rate (91%) than
ceftriaxone in combination with azithromycin (98%).5 For those
administered gentamicin, clearance was better for those with a
genital infection (94%), compared with pharyngeal (80%) and
rectal (90%) gonorrhoea. Even though it is not possible to differen-
tiate between the effectiveness of the individual agents in a two-
component regimen, it is unlikely that azithromycin consistently
provided sufficient microbiological cure when gentamicin failed to
treat. These results cast doubt on whether the use of azithromycin
in combination with ceftriaxone for the treatment of gonorrhoea is
appropriate, particularly for extragenital infections.
Antimicrobial susceptibility testing is used to predict response
to treatment, but just one other study has assessed the associ-
ation between the laboratory measurement of MIC and the micro-
biological cure of N. gonorrhoeae infection when combination
therapy was used.14 Preliminary analysis of the G-ToG trial data
did not reveal a clear relationship between gentamicin, ceftriaxone
or azithromycin MICs in vitro and N. gonorrhoeae clearance, and
most of the isolates cultured post-treatment were susceptible
according to EUCAST breakpoints.5 To investigate the relationship
between MIC and clinical outcome further, MIC analysis was per-
formed on N. gonorrhoeae isolates from all G-ToG trial participants
who were culture positive before they received treatment, and
also on post-treatment isolates from those for whom treatment
failed. The aim of this analysis was to identify any relationship be-
tween response to treatment and the MICs of azithromycin, cef-
triaxone and gentamicin, as well as to determine any differences
in the MICs for isolates from patients in the two treatment arms
and from different infection sites.
Materials and methods
Methods for the G-ToG trial are described elsewhere.5,15 Briefly, a blinded,
non-inferiority randomized trial was performed in 14 sexual health clinics in
England. Participants who had a diagnosis of uncomplicated gonorrhoea
were randomized to receive gentamicin 240 mg or ceftriaxone 500 mg,
both in combination with 1 g oral azithromycin. The primary outcome was
demonstration of N. gonorrhoeae clearance by an NAAT at all infected sites
2 weeks post-treatment. Swabs were also taken for gonococcal culture
from patients at the baseline and at a 2 week post-treatment visit.
A total of 720 participants were enrolled to G-ToG and primary outcome
data were available for 598 randomized to receive ceftriaxone/azithromy-
cin (n=306) or gentamicin/azithromycin (n=292). Overall, 333 viable
gonococcal cultures were available from 279 participants, of whom 145
received ceftriaxone/azithromycin and 134 received gentamicin/azithro-
mycin. The number of these participants who cleared infection was 261.
Four participants (6 isolates) and 14 participants (17 isolates) did not clear
infection in the ceftriaxone/azithromycin and gentamicin/azithromycin
arms, respectively. The majority of isolates (n=329) were collected at the
baseline visit, before treatment. Two isolates from the 2 week follow-up
visit were included from two participants who did not have a pre-treatment
isolate available, with the assumption that the isolates would be the same
at the baseline and follow-up visit. A further two isolates from the follow-up
visit were available; however, these were not included as baseline visit iso-
lates were available from the two participants. All analyses were therefore
based on 331 isolates.
N. gonorrhoeae isolates
Frozen isolates were sent to PHE from the primary diagnostic laboratory
associated with each sexual health clinic for antimicrobial susceptibility
testing. Isolates were retrieved on GC agar base (BD DifcoTM; BD,
Wokingham, UK) with 1% Vitox (Oxoid Ltd, Basingstoke, UK) and the iden-
tity of the isolates was confirmed using Gram staining, oxidase testing and
MALDI-TOF (Bruker, Billerica, MA, USA). After an additional subculture, a 0.5
MacFarland suspension was created in saline, and azithromycin, ceftriax-
one and gentamicin MICs were determined by Etest (bioMe´rieux UK Ltd,
Basingstoke, UK) on GC agar base with 1% Vitox. Inoculated plates were
incubated (36C in 5% CO2) and the MICs were recorded the following day.
MICs were rounded up to the nearest doubling dilution and susceptibility
categories for azithromycin (resistance MIC >0.5 mg/L) and ceftriaxone
(resistance MIC >0.125 mg/L) were assigned using EUCAST 2018 break-
points.16 No EUCAST breakpoints were available for gentamicin.
Statistical analysis
The number of isolates cleared/not cleared at each azithromycin, ceftriax-
one and gentamicin MIC by treatment arm was established (Table 1).
The association between in vitro categorical azithromycin resistance
(MIC >0.5 mg/L) and N. gonorrhoeae clearance (yes/no) was explored using
Fisher’s exact test. Linear regression was used to compare azithromycin,
ceftriaxone and gentamicin continuous MICs with each treatment received
and N. gonorrhoeae clearance. For the linear regression model, the MICs
were log-transformed due to skewed data. Estimates from the linear re-
gression on the log-transformed MICs correspond to a ratio of geometric
mean MIC between two groups, such as those who received gentamicin/
azithromycin and cleared infection and those who received gentamicin/
azithromycin and did not clear infection.
To investigate whether baseline MIC modified the effect of the random-
ized treatment arm (gentamicin/azithromycin or ceftriaxone/azithromycin)
on N. gonorrhoeae clearance (the outcome), we fitted separate logistic
regression models for each of the three antimicrobials (azithromycin,
ceftriaxone and gentamicin) that included an interaction term between
baseline log-transformed MIC and the treatment arm. Evidence of an inter-
action term (P<0.05) will indicate a differential association (for clearance
and baseline MIC) between the two treatment arms.
To investigate the effect of potential reinfection following treatment, a
sensitivity analysis was performed by excluding 10 isolates from six partici-
pants who did not clear infection and who reported sex without consistent
condom use before test of cure. Analyses were performed using Stata 13.1
(StataCorp, Texas, USA). Statistical analyses were not adjusted for multiple
comparisons, therefore results should be interpreted with caution.
Ethics
The trial was approved by Health Research Authority South Central – Oxford
C Research Ethics Committee (14/SC/1030).
Results
Participants administered ceftriaxone and azithromycin
Within isolates from participants receiving ceftriaxone/azithromy-
cin, there was little evidence of any difference in azithromycin
(P=0.187) categorical resistance (Figure 1) (note: no ceftriaxone
Cole et al.
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resistance was identified). There was little evidence of any differ-
ence in the geometric mean MIC of azithromycin or ceftriaxone be-
tween those with cleared versus non-cleared infection (Table 2).
The six treatment failures in six participants who received
ceftriaxone/azithromycin were from genital (three isolates), rectal
(two isolates) and pharyngeal (one isolate) sites. Three of the six
participants gave a history of unprotected sex following treatment,
one of whom had sex with a new partner and two with a previous
partner.
Participants administered gentamicin and azithromycin
Infections in 14 participants (17 isolates; 6 genital, 6 pharyngeal
and 5 rectal) were not cleared following treatment with
Table 1. Percentage and number of isolates cleared/not cleared at each azithromycin, ceftriaxone and gentamicin MIC by treatment arm
MIC (mg/L)
Ceftriaxone/azithromycin Gentamicin/azithromycin
% (n) cleared % (n) not cleared % (n) cleared % (n) not cleared
Azithromycin
0.016 100 (1) 0
0.032 100 (7) 0 100 (7) 0
0.064 100 (30) 0 95.8 (23) 4.2 (1)
0.125 89.1 (41) 10.9 (5) 95.7 (44) 4.3 (2)
0.25 97.9 (46) 2.1 (1) 85.4 (35) 14.6 (6)
0.5 100 (37) 0 82.8 (24) 17.2 (5)
1 100 (7) 0 62.5 (5) 37.5 (3)
4 100 (1) 0
Ceftriaxone
0.002 92.3 (24) 7.7 (2) 96.2 (25) 3.8 (1)
0.004 98.8 (81) 1.2 (1) 93.2 (55) 6.8 (4)
0.008 90.0 (27) 10.0 (3) 85.7 (24) 14.3 (4)
0.016 100 (22) 0 81.5 (22) 18.5 (5)
0.032 100 (14) 0 80.0 (12) 20.0 (3)
0.064 100 (1) 0
0.125 100 (1) 0
Gentamicin
1 100 (3) 0 100 (3) 0
2 92.7 (51) 7.3 (4) 97.4 (38) 2.6 (1)
4 98.2 (110) 1.8 (2) 85.5 (94) 14.5 (16)
8 100 (5) 0 100 (3) 0
16 100 (1) 0
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Figure 1. Distribution of (a) ceftriaxone or (b) azithromycin MIC (mg/L) by clearance/non-clearance of N. gonorrhoeae in those who received ceftriax-
one and azithromycin.
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gentamicin/azithromycin. Of these treatment failures, azithromy-
cin resistance in vitro (MIC >0.5 mg/L) was found in three isolates
from three participants (3/17, 18%). Five isolates from five partici-
pants (5/138, 4%) with cleared infection were resistant to azithro-
mycin in vitro (Fisher’s exact test, P=0.044) (Figure 2a). However,
there was less evidence of an association between category of
azithromycin resistance (MIC >0.5 mg/L) and treatment failure
when the isolates from participants who had sex since entry into
the trial were removed (n=2; azithromycin MIC of 0.5 and 1.0 mg/L,
P=0.141).
There was strong evidence of a higher geometric mean MIC of
azithromycin for isolates from participants who had received
gentamicin/azithromycin and where infection was not cleared
compared with those with cleared infection, with a ratio of 1.95
(95% CI 1.28–2.97, P=0.002) (Table 2). This higher geometric
mean MIC of azithromycin remained when those who had unpro-
tected sex following treatment were excluded (ratio 2.23, 95%
CI 1.30–3.81, P=0.004).
For those who received gentamicin/azithromycin, the gentami-
cin MICs were mostly 4 mg/L [16/17 (94%, range 2–4 mg/L)] in the
non-clearance group, with 94/138 (68%, range 1–8 mg/L) in the
clearance group (Figure 2b). Azithromycin MICs were 0.125, 0.25
and 0.5 mg/L for three isolates with gentamicin MICs of 8 mg/L
and infections in all three patients were cleared. There was little
evidence of any difference between the geometric mean MIC
of gentamicin and clearance of infection either overall or after
excluding those with risk of reinfection (Table 2).
Site of infection
The azithromycin MIC distribution and geometric mean MIC were
assessed by anatomical site of infection independent of treatment
and response (Figure 3, Table 2). The geometric mean MIC was
higher in those with pharyngeal compared with genital infection,
both in those who received ceftriaxone/azithromycin (ratio 1.80,
95% CI 1.26–2.57, P=0.002) and in those given gentamicin/
azithromycin (ratio 1.79, 95% CI 1.20–2.68, P=0.005) (Table 2).
Even though the numbers are very small, the azithromycin
MICs were higher in isolates from those who received gentamicin/
azithromycin and failed treatment in the pharynx, with a mode of
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Figure 2. Distribution of (a) azithromycin or (b) gentamicin MIC (mg/L) by clearance/non-clearance of N. gonorrhoeae in those who received gentami-
cin and azithromycin.
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0.5 mg/L compared with 0.25 mg/L in the cleared pharyngeal in-
fection group (Figure 4). A higher geometric mean MIC of azithro-
mycin was also observed in those who did not clear pharyngeal
infection compared with those with cleared pharyngeal infection,
with a ratio of 2.48 (95% CI 1.44–4.27, P=0.003) (Table 2). Strong
evidence of an association remained when the isolates from
participants who reported unprotected sex following treatment
were excluded (ratio 2.91, 95% CI 1.68–5.06, P=0.001).
In participants who received gentamicin/azithromycin, the cef-
triaxone geometric mean MIC was also higher in the pharynx com-
pared with genital isolates (ratio 1.59, 95% CI 1.06–2.37, P=0.025)
(Table 2) and the geometric mean MICs of gentamicin were higher
for rectal isolates compared with genital isolates (ratio 1.18, 95%
1.02–1.37, P=0.03) (Table 2). Higher geometric mean MICs of cef-
triaxone were not identified in any infection site for isolates from
the ceftriaxone/azithromycin arm (Table 2).
Interaction between treatment and baseline MIC
We used the logistic regression model to investigate whether
baseline azithromycin, ceftriaxone or gentamicin MIC modified the
effect of randomized treatment on N. gonorrhoeae clearance. We
identified evidence of interaction between treatment arm and
baseline azithromycin MIC (OR 0.246, 95% CI 0.078–0.783,
P=0.018); as the baseline azithromycin MIC increased, gentamicin/
azithromycin became less effective at clearing N. gonorrhoeae
compared with ceftriaxone/azithromycin. Evidence of this inter-
action remained in the sensitivity analysis that excluded those
with possible reinfection (OR 0.169, 95% CI 0.029–0.034, P=0.029).
Initial evidence of an interaction was identified between baseline
gentamicin MIC and the gentamicin/azithromycin treatment arm
(OR 0.045, 95% CI 0.003–0.634, P=0.022) but little evidence
remained when the isolates from participants who had sex since
entry into the trial were removed (P=0.120). There was little evi-
dence of an interaction between baseline ceftriaxone MIC and the
two treatment arms.
Discussion
We found that as the azithromycin MIC increased the gentamicin/
azithromycin treatment was less effective than ceftriaxone/azith-
romycin at clearing N. gonorrhoeae. This result is not unexpected
when we consider the lower cure rate (91%) using gentamicin/
azithromycin compared with ceftriaxone/azithromycin (98%) that
was previously established from the large trial of gonorrhoea
treatment.5 What was unexpected was the poor predictive value
of categorical resistance for azithromycin and ceftriaxone in vitro,
and higher gentamicin MICs in the absence of breakpoints, in
predicting treatment failure for participants. Of the 23 isolates
recovered following treatment, only three (13%) would have been
predicted using in vitro susceptibility testing. Reinfection (as
opposed to antibiotic treatment failure) may have occurred in
some individuals, but is unlikely to account for all participants who
remained infected at follow-up. Specifically, excluding those with
a history of post-treatment unprotected intercourse made little
difference to the predictive accuracy of pre-treatment in vitro sus-
ceptibility testing. In addition, the overall higher treatment failure
rate in individuals randomized to receive gentamicin/azithromycin
(25/292; 9%) compared with ceftriaxone/azithromycin (7/306;
2%) also suggests that the majority of cases where infection failed
to clear in those given gentamicin/azithromycin was due to lack of
antibiotic efficacy rather than reinfection,5 further supported by
the evidence of an interaction between MIC and treatment arm.
The geometric mean MIC of azithromycin was also significantly
higher for isolates from the group failing therapy; however, this is
of little practical value for clinicians in selecting therapy.
Azithromycin MICs for 9 of 17 isolates from participants who failed
treatment following gentamicin/azithromycin were categorized as
susceptible (range 0.064–0.25 mg/L). This lack of correlation be-
tween clinical outcome and azithromycin MICs has been observed
previously in Australia17 where five patients who failed treatment
with 1 g azithromycin had isolates with azithromycin MICs of
0.125–0.25 mg/L. Additionally, EUCAST have recently removed the
clinical breakpoints for azithromycin from the 2019 breakpoint
tables,18 in part due to the poor correlation of azithromycin MICs
and clinical outcome as well as a lack of pharmacokinetic and
pharmacodynamic models, and because azithromycin is often
used in conjunction with another effective agent. Both EUCAST18
and CLSI4 have established the epidemiological cut-off (ECOFF) at
1 mg/L; the point at which the WT distribution ends and the
distribution of isolates with acquired azithromycin resistance
mechanisms begins. It should be noted that while EUCAST has no
breakpoints for azithromycin, CLSI regard 1 mg/L as the suscep-
tible breakpoint.4
It is likely that azithromycin 1 g failed to provide microbiological
cure when gentamicin treatment was unsuccessful despite previ-
ous studies of azithromycin demonstrating effectiveness.19 This
suggests that the use of 1 g azithromycin in dual therapy, which is
in widespread use8 to delay the emergence of resistance to cef-
triaxone, needs to be reviewed. Consequently, the UK gonorrhoea
management guidelines have recently been revised and recom-
mend removal of azithromycin from the first-line therapy (https://
www.bashhguidelines.org/media/1208/gc-2019.pdf). It should be
noted that the EUCAST 2018 breakpoint for azithromycin was
based on using the 2 g dose in monotherapy.3 The 2 g dose for
gonorrhoea treatment may be more effective and provide more
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clearance of pharyngeal isolates from those who received gentamicin
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confidence in the predictive value of the MICs, albeit with a high
rate of reported gastrointestinal side effects.14,20 However, a
Japanese study established an eradication rate of just 93.8% in
men with gonococcal urethritis when a single 2 g dose of azithro-
mycin extended-release formation was administered.21 The wide-
spread use of azithromycin for N. gonorrhoeae treatment has also
been challenged due to a number of issues: (i) the ease with which
azithromycin resistance can emerge both in vivo22–24 and
in vitro;25 (ii) reports of increases in azithromycin resistance both
nationally26 and globally;27–29 (iii) sustained transmission of
isolates with high-level azithromycin resistance in England11 and
Hawaii;30 and (iv) the recent emergence of isolates with both
high-level ceftriaxone and azithromycin resistance in England13
and Australia.31
Azithromycin’s long half-life of 67 h32 has been postulated to
select for resistance.22 For example, any surviving gonococci, or
those acquired from infection some days after treatment with
azithromycin, may be exposed to subMIC levels of azithromycin.
The presence of prolonged low-level drug concentrations post-
treatment also has a potential impact on the emergence of
azithromycin resistance for other sexually transmitted infections
(STIs) in patients who are, or become, coinfected.33
Resistance breakpoints for gentamicin have not been deter-
mined and our data highlight the difficulty in establishing these
breakpoints, particularly as gentamicin was used as part of
combination therapy. Most participants (68%, 94/138) with
cleared infections harboured isolates with MICs4 mg/L, whereas
in isolates from participants who failed treatment the gentamicin
MICs were 4 mg/L in all but one. Isolates with MICs above the ten-
tative gentamicin resistance breakpoint of >16 mg/L34 were not
observed from participants experiencing treatment failure.
Gentamicin is infrequently used for gonorrhoea treatment outside
of Malawi35 and Zambia,36 so there is currently no selection pres-
sure from gentamicin usage to induce resistance in gonococci iso-
lated from patients in the UK. Treatment failure due to poor tissue
penetration, rather than resistance, seems more plausible. The
gentamicin MIC distribution in this study was similar to a 2016
European study10 although it is difficult to determine potential
breakpoints from this data when gentamicin was used in combin-
ation with azithromycin. Our data suggest that an increased dos-
age to achieve higher drug levels, especially at extragenital sites,
needs further investigation. Pragmatically, however, the large vol-
ume of injection for gentamicin (6 mL for a 240 mg dose) would
probably require a larger dose to be delivered via an additional in-
jection or necessitate a reformulation of the drug into a smaller
volume. A move away from single-dose, directly observed therapy
to multiple-dose regimens to increase the effectiveness of antimi-
crobials in the pharynx could also be further explored.37
The proportion of patients who failed treatment despite having
infections, particularly at the pharynx, caused by isolates ‘suscep-
tible’ to gentamicin and azithromycin shows that MICs alone can-
not predict outcome. As stated previously,17 there may be
pharmacokinetic properties of azithromycin in tissues, especially of
the pharynx, that prevent the use of MICs to predict treatment out-
come reliably. This may also apply to gentamicin. It is possible that
alternative genetic markers identified through sequencing might
better predict treatment outcome but this remains speculative.
As well as differences in tissue penetration, there are a number of
possible reasons why the gentamicin/azithromycin combination
was less effective at the pharynx: ‘protection’ of N. gonorrhoeae by
commensal organisms or within gonococcal biofilms, exposure to
aminoglycoside-modifying enzymes from other organisms38 and
possibly some other inducible resistance such as mutations in
genes within an intrinsic resistome similar to that observed with
Acinetobacter baumannii;39 results from ongoing molecular
studies should help to resolve the mechanism(s) by which the
gonococcal strains resisted clearance by gentamicin. Although cef-
triaxone remained effective at the pharynx, some of these factors
may also apply to other antimicrobials that have not been as
effective when treating pharyngeal gonorrhoea.40–42
Interestingly we found higher geometric mean MICs of azithro-
mycin in the pharynx compared with genital isolates in both
treatment arms, and higher ceftriaxone MICs in the pharynx in the
gentamicin/azithromycin arm. Higher MICs in the pharynx have
been demonstrated in other studies43–46 as it is postulated the
throat is a hotspot for resistance due to the transfer of resistance
determinants from commensal Neisseria and possibly selection of
resistance in the pharynx is more likely due to reduced tissue pene-
tration, which subsequently exposes the bacteria to suboptimal
doses of antibiotic. The higher pharyngeal azithromycin MICs may
have contributed to the reduced N. gonorrhoeae clearance in the
gentamicin/azithromycin arm, suggesting that different break-
points for different anatomical sites could be considered. It should,
however, be noted that the clearance of the gonococci in the cef-
triaxone/azithromycin treatment arm was not hindered by these
higher MICs, and not all studies have detected differences in MIC
according to anatomical site.47,48
As previously mentioned, a limitation of this study was not
adjusting for multiplicity, so the results should be interpreted with
caution. Another limitation is the small number of isolates avail-
able for MIC analysis; only 39% of participants had an isolate, so
we should be wary that the culture dataset may not be represen-
tative of the whole study population, especially for extragenital
infections. It is well established that culture is less sensitive than
NAATs49 and an analysis from the Gonococcal Resistance to
Antimicrobials Surveillance Programme (GRASP) dataset revealed
that only 46% of patients had culture-positive infections.50 The
culture-positive participants in our dataset may have had a higher
bacterial load or more ‘virulent’ bacteria, so the distribution of MICs
for pharyngeal isolates may be spurious. However, the characteris-
tics of participants with and without any positive culture isolates at
the baseline visit revealed that both groups were well matched;
exceptions were the more frequent presence of symptoms in the
culture-positive group (as expected), and the lower proportion of
MSM in the culture-positive group (see Table S1, available as
Supplementary data at JAC Online, describing the baseline charac-
teristics for participants with and without any positive culture
isolates at the first visit). The proportion of MSM in this group rough-
ly corresponds with the epidemiological surveillance1 data
and overall the dataset is one of the largest available that directly
evaluates MICs in relation to clinical outcome. The robust and
standardized approach to data collection and laboratory testing is
an additional strength of the study.
Decreasing azithromycin and ceftriaxone susceptibility is being
observed globally, therefore alternative treatment options and
strategies are urgently required. Even though gentamicin with
azithromycin is a suitable alternative in uncomplicated genital
infection, serious consideration of different dosages for different
MIC and clinical outcome in gonococcal infection JAC
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sites or extended regimens to ensure N. gonorrhoeae is cleared at
all sites is warranted. This is particularly relevant following recent
reports of treatment failure with ceftriaxone in patients with pha-
ryngeal gonorrhoea compared with successful treatment of their
urogenital infection.12,13 Clinicians also need to be aware that
MICs are not always predictive of gonorrhoea clinical failure, espe-
cially for azithromycin and gentamicin, which may also impact the
effectiveness of point-of-care tests for resistance-guided therapy.
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